OncLive

Articles

Second-Line Treatment for HER2+ MBC

December 15th 2021

Variables that affect second-line treatment decisions in HER2-positive metastatic breast cancer.

Treating After T-DM1 in Relapsed/Refractory HER2+ MBC

December 15th 2021

Recommendations regarding how to best treat a patient with HER2-positive metastatic breast cancer who has previously received multiple lines of therapy, including T-DM1.

Notable Treatment Advances in HER2+ MBC

December 6th 2021

Reactions to presentations from ESMO 2021 that demonstrated the potential of various new treatment approaches for use in HER2-positive metastatic breast cancer.

Implications of HER2CLIMB Updates on Treating HER2+ MBC

December 6th 2021

Key takeaways from updates to the HER2CLIMB study in HER2-positive metastatic breast cancer.

Educating Patients About Novel Targeted Therapies for CLL

December 6th 2021

The importance of multidisciplinary care in chronic lymphocytic leukemia and proper patient education on adverse events associated with novel targeted therapies.

Targeted Therapies for CLL: Managing Adverse Events

December 6th 2021

Common toxicities associated with novel targeted therapies, such as BTK inhibitors, used to treat chronic lymphocytic leukemia, and recommendations on how to manage with dose adjustments.

Frontline Therapy for CLL: Chemotherapy-Free Regimens

December 6th 2021

Recommendations for using novel targeted therapies to treat chronic lymphocytic leukemia in the frontline setting.

Approaches to Initiating Therapy for a Patient With CLL and Worsening Symptoms

December 6th 2021

Oncology hematology health care professionals from Memorial Sloan Kettering Cancer Center discuss how to manage a 67-year-old woman with chronic lymphocytic leukemia who develops progressive fatigue and night sweats.

Counseling Patients With Newly Diagnosed CLL

December 6th 2021

Staging criteria used in the diagnosis of chronic lymphocytic leukemia, and recommendations for talking with patients about molecular testing results and goals of therapy.

CLL: Diagnostic and Prognostic Criteria

December 6th 2021

An overview of tests used to evaluate patients for chronic lymphocytic leukemia and, consequently, inform treatment decisions.

CLL: A Heterogeneous Disease

December 6th 2021

Oncology hematology health care professionals from Memorial Sloan Kettering Cancer Center react to the variation in symptoms that patients suspicious of chronic lymphocytic leukemia present with.

Treatment Sequencing Strategies in HER2+ MBC

December 1st 2021

Treatment algorithms used in clinical practice by breast oncologists to best approach and subsequently treat patients with HER2-positive metastatic breast cancer.

Preferences for Treating Relapsed HER2+ MBC

December 1st 2021

A panel of breast oncologists highlight their therapy preferences for a woman with HER2-positive metastatic breast cancer previously treated with docetaxel-trastuzumab-pertuzumab followed by paclitaxel and cisplatin.

Dr. Horn on the Role of Mobocertinib in NSCLC

August 28th 2020

Leora Horn, MD, MSc, FRCPC, discusses the role of mobocertinib in patients with non–small cell lung cancer.

The NYU Cancer Institute Joins OncLive's Strategic Alliance Partnership

October 29th 2013

Newest OncLive partner is a renowned translational cancer center that is at the forefront of comprehensive cancer treatment and research into advanced targeted therapies.

The Cancer Therapy & Research Center at the University of Texas Health Science Center Joins OncLive's Strategic Alliance Partnership

September 25th 2013

World-class cancer research and treatment center is the latest to partner with OncLive to promote its research, events, and initiatives

Building Blocks of a Biotech: CytRx Executives Talk About 3 Agents for Multiple Tumors

July 29th 2011

Amid growing cost pressures in the pharmaceutical industry, many small companies are playing an increasingly active role in drug development.

3 Questions for Srdan Verstovsek, MD, PhD

July 26th 2011

Srdan Verstovsek, MD, PhD, is a medical oncologist and associate professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center in Houston.

Ruxolitinib Results Promising in 2 Myelofibrosis Studies

July 25th 2011

Ruxolitinib, an investigational JAK inhibitor, demonstrated significant benefits for patients with myelofibrosis.

4 Questions for Martine Piccart-Gebhart, MD, PhD: Noted Breast Cancer Researcher Has Bright Hopes for HER2 Targets

June 27th 2011

Martine Piccart-Gebhart, MD, PhD is a professor of oncology at the Universite Libre de Bruxelles and director of the Medicine department at the Jules Bordet Institute in Brussels, Belgium.